Immix Biopharma Sees Positive Data for Pancreatic Cancer Treatment in Mouse Trial
January 25 2022 - 11:15AM
Dow Jones News
By Chris Wack
Immix Biopharma Inc. on Tuesday released data showing that
IMX-110 plus anti-PD-1 produced extended median survival in a
genetic pancreatic cancer mouse model, bolstering its planned 2022
clinical trial.
The company said it would collaborate with BeiGene for a 2022
Phase 1b/2a combination clinical trial of IMX-110 + BeiGene
anti-PD-1 tislelizumab in advanced solid tumors.
"We believe this upcoming combination clinical trial will allow
us to rapidly expand into multiple oncology indications, " ImmixBio
Chief Executive Ilya Rachman said.
The U.S. Food and Drug Administration has approved orphan drug
designation for IMX-110 for the treatment of soft tissue sarcoma,
and approved rare pediatric disease designation to IMX-110 for the
treatment of a life-threatening pediatric cancer in children,
rhabdomyosarcoma.
As of January, anti-PD-1 tisleizumab has been approved or
granted conditional approval in six cancer indications in China,
including non-squamous non-small cell lung cancer, squamous NSCLC,
classical Hodgkin's lymphoma, Hepatocellular Carcinoma, and
urothelial carcinoma.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 25, 2022 11:00 ET (16:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2023 to Apr 2024